Adagrasib versus docetaxel in KRAS(G12C)-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial. Barlesi F, Yao W, Duruisseaux M, Doucet L, et al. Lancet 2025;406:615-626.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Barlesi F, Yao W, Duruisseaux M, Doucet L, et al. Adagrasib versus docetaxel in KRAS(G12C)-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial. Lancet 2025;406:615-626.
PMID: 40783289